Table 4.
Univariate and multivariate analyses of risk factors for progression free survival.
| Variable | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95% CI) | p valuea | HR (95% CI) | p valuea | |
| Age | 0.95 (0.89–1.02) | 0.158 | ||
| Male gender | 1.07 (0.34–3.37) | 0.915 | ||
| Never smoker | 1.31 (0.41–4.12) | 0.650 | ||
| ECOG PS | ||||
| 0–2 | 1 | |||
| 3–4 | 6.00 (1.30–27.72) | 0.022 | 6.78 (1.29–35.49) | 0.024 |
| Brain mets before ICI | 1.02 (0.27–3.86) | 0.980 | ||
| PD-L1 | ||||
| < 1% | 3.84 (0.77–19.33) | 0.103 | ||
| 1–49% | 2.10 (0.34–12.91) | 0.424 | ||
| ≥ 50% | 1 | |||
| CD4/CD8 ratio | ||||
| < 1.93 | 1 | |||
| ≥ 1.93 | 0.27 (0.08–0.87) | 0.028 | 0.25 (0.07–0.86) | 0.027 |
ECOG PS, Eastern Cooperative Oncology Group performance status; mets, metastasis; ICI, immune checkpoint inhibitor; HR, hazard ratio; CI, confidence interval.
aProbability value by Cox regression model.